Durham, NC – Oncologists and all professionals involved in cancer treatment know that personalized cancer care is the wave of the future—or is it already here? To answer that question, this year’s Fifth Annual Meeting of the Society for Translational Oncology (STO) is dedicated to the theme, “Perspectives on Progress: Using Genomics to Guide Clinical Therapy.” The meeting will be hosted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at Ohio State’s Biomedical Research Tower (BRT) in Columbus, Ohio, April 10-11, 2015.
“We have assembled nationally known researchers to provide their perspectives on how to provide practical application of genomic data to patients that we see in clinic every day,” says Richard M. Goldberg, MD, co-chairman of STO and physician-in-chief at Ohio State’s James Cancer Hospital and Solove Research Institute. “Insights into the application of targeted agents to genetic drivers are changing practice today and will change it even more as we harness the practical application of this emerging field.”
The meeting includes a keynote lecture on translational research that is opening the way to personalized cancer care in the clinic. David Neil Hayes, MD, MPH, an associate professor of medicine at the University of North Carolina School of Medicine and a member of UNC Lineberger, will speak on “Lessons from the Cancer Genome Atlas.” Dr. Hayes will focus on lessons learned from the large cancer sequencing projects including The Cancer Genome Atlas which has recently completed sequencing of over 11,000 human cancers. The intensive two-day program also includes expert updates on timely topics such as biologic and genomic heterogeneity, molecular markers in the clinic and the opportunities for Precision Cancer Medicine.
Attendees will have the opportunity to engage one-on-one with key leaders in translational oncology and genomic research initiatives as well as tour Ohio State’s new transformational cancer hospital. Considered a model for cancer hospitals to come, the new 21 floor, 1.1 million square foot James Cancer Hospital and Solove Research Institute opened in December 2014. The hospital integrates a robust clinical research enterprise and highly subspecialized care model into one building. Other hospital highlights include a fully integrated cancer emergency department, state-of-the art surgical center and an expanded, above-ground radiation therapy center.
“Many top talents in oncology have joined Ohio State in anticipation of this hospital’s opening, including David Carbone, MD, PhD (lung cancer); Raphael Pollack, MD, PhD (sarcoma); John Byrd, MD, (CLL); and many others who will participate in the annual Society of Translational Oncology meeting,” says Goldberg.
Oncology clinicians, researchers, nurse practitioners, oncology trainees and other medical or research staff involved in cancer care are invited to attend this conference to exchange ideas and garner a better understanding of how personalized medicine and cancer genomics can impact patient care.
Click here to preview the agenda.
To register online, visit http://bit.ly/STO5AnnualMeeting
###
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: www.sto-online.org.
About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now celebrating its twentieth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: www.theoncologist.com.
About The OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. In their last review, the NCI rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. For more information, please visit cancer.osu.edu.
Help employers find you! Check out all the jobs and post your resume.
